Gen9 And Amyris, Inc. Announce Supply Agreement For Synthetic DNA
Amyris joins Gen9’s MAP program to purchase mass quantities of synthetic DNA for development of high performance renewable products
CAMBRIDGE, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gen9 and Amyris today announced an agreement for the supply of multiple megabases of synthetic DNA content. The DNA is being supplied for use in Amyris, Inc.’s (Nasdaq: AMRS) microbial engineering pipeline for the development of products that improve performance and enable sustainable growth for some of the world’s leading brands. The collaboration is part of Gen9’s MAP program, fueled by the BioFab® DNA synthesis technology, which provides valuable, high-quality synthetic DNA constructs for industrial-scale use.
“Amyris is developing a wide range of innovative products with their platform, from plant-derived cosmetic ingredients, to renewable lubricants, to novel biopharmaceuticals”
“A fast, reliable source of high-quality synthetic DNA constructs is an essential component of our microbial engineering platform for the production of high value molecules. Gen9 consistently provides that for us,” said Joel Cherry, Amyris President of Research and Development. “With the DNA synthesis throughput and economics that Gen9 offers, we are able to engineer and test new strains more cost effectively, using them to rapidly identify the highest-performing microbes and allowing us to bring sustainable products to market more quickly.”
“Amyris is developing a wide range of innovative products with their platform, from plant-derived cosmetic ingredients, to renewable lubricants, to novel biopharmaceuticals,” said Kevin Munnelly, President and CEO of Gen9. “We are excited that Gen9 DNA will be utilized to develop products that will solve some of the most important global challenges we face today.”
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
Amyris and the Amyris logo are registered trademarks of Amyris, Inc.